These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20167561)

  • 1. Delta-like 4 and vasohibin 1: two endothelium-produced negative regulators of angiogenesis with distinctive roles.
    Sato Y
    Eur Cytokine Netw; 2009 Dec; 20(4):220-4. PubMed ID: 20167561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vasohibin family: Novel regulators of angiogenesis.
    Sato Y
    Vascul Pharmacol; 2012; 56(5-6):262-6. PubMed ID: 22286022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasohibin: the feedback on a new inhibitor of angiogenesis.
    Kerbel RS
    J Clin Invest; 2004 Oct; 114(7):884-6. PubMed ID: 15467823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is vasohibin-1 for more than angiogenesis inhibition?
    Sato Y
    J Biochem; 2011 Mar; 149(3):229-30. PubMed ID: 21217147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells.
    Sato Y; Sonoda H
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):37-41. PubMed ID: 17095714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vasohibin family: a novel family for angiogenesis regulation.
    Sato Y
    J Biochem; 2013 Jan; 153(1):5-11. PubMed ID: 23100270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis.
    Watanabe K; Hasegawa Y; Yamashita H; Shimizu K; Ding Y; Abe M; Ohta H; Imagawa K; Hojo K; Maki H; Sonoda H; Sato Y
    J Clin Invest; 2004 Oct; 114(7):898-907. PubMed ID: 15467828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Vasohibin Family.
    Sato Y
    Pharmaceuticals (Basel); 2010 Feb; 3(2):433-440. PubMed ID: 27713261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes.
    Wakusawa R; Abe T; Sato H; Yoshida M; Kunikata H; Sato Y; Nishida K
    Am J Ophthalmol; 2008 Aug; 146(2):235-243. PubMed ID: 18486097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells.
    Shimizu K; Watanabe K; Yamashita H; Abe M; Yoshimatsu H; Ohta H; Sonoda H; Sato Y
    Biochem Biophys Res Commun; 2005 Feb; 327(3):700-6. PubMed ID: 15649403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on endogenous inhibitors of angiogenesis.
    Sato Y
    Endothelium; 2006; 13(2):147-55. PubMed ID: 16728331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin.
    Shibuya T; Watanabe K; Yamashita H; Shimizu K; Miyashita H; Abe M; Moriya T; Ohta H; Sonoda H; Shimosegawa T; Tabayashi K; Sato Y
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1051-7. PubMed ID: 16528006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasohibin prevents arterial neointimal formation through angiogenesis inhibition.
    Yamashita H; Abe M; Watanabe K; Shimizu K; Moriya T; Sato A; Satomi S; Ohta H; Sonoda H; Sato Y
    Biochem Biophys Res Commun; 2006 Jul; 345(3):919-25. PubMed ID: 16707096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-like 4/Notch signaling and its therapeutic implications.
    Yan M; Plowman GD
    Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin.
    Sonoda H; Ohta H; Watanabe K; Yamashita H; Kimura H; Sato Y
    Biochem Biophys Res Commun; 2006 Apr; 342(2):640-6. PubMed ID: 16488400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties.
    Dhanabal M; Jeffers M; LaRochelle WJ; Lichenstein HS
    Biochem Biophys Res Commun; 2005 Jul; 333(2):308-15. PubMed ID: 15950186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
    Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
    Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
    Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.